目的:评价复方苦参注射液应用于肝癌介入治疗的价值和不良反应。方法:选用本院收治的90例原发性肝癌患者为研究对象,随机分为对照组和观察组,对照组单用介入治疗,同时给于常规护肝治疗,观察组在介入治疗的前提下联合复方苦参注射液静滴。治疗一个周期后分别以RECIST和NCICTC标准观察和评价两组的治疗疗效和不良反应。结果:两组的CR均占6.67%,但是观察组的CR+PR为55.56%明显高于对照组的46.67%,两者相比差异具有统计学意义。在不良反应上,观察组的不良反应发生率明显低于对照组,且差异显著(P<0.05)。结论:复方苦参注射液联合介入疗法应用于肝癌治疗能明显增加疗效,还可以减低不良反应的发生率,值得临床借鉴。 Objective: To evaluate the value and adverse reactions of Compound Kushen Injection in the interventional therapy of liver cancer. Methods: Ninety patients with primary hepatocellular carcinoma who were admitted to our hospital were selected as control group and observation group. The control group was treated with interventional therapy alone, while the control group was given conventional hepatoprotective therapy. Under the premise of interventional therapy, Compound Compound Kushen Injection intravenous infusion. After one cycle of treatment, the curative effects and adverse reactions of both groups were observed and evaluated by RECIST and NCICTC respectively. Results: CR was 6.67% in both groups, but CR + PR in observation group was 55.56%, which was significantly higher than that in control group (46.67%). The difference between the two groups was statistically significant. Adverse reactions in the observation group adverse reaction rate was significantly lower than the control group, and the difference was significant (P <0.05). Conclusion: Compound Kushen injection combined with interventional therapy for liver cancer treatment can significantly increase the efficacy, but also can reduce the incidence of adverse reactions, it is worth learning from.